PTC Therapeutics Added to NASDAQ Biotechnology Index
Canterbury Park : Approximately shares changed hands, a 100.0 decrease from its 65-day average volume. The shares remained unchanged at $10.78. DNB Financial Corp. : Approximately shares changed hands, a 99.9 decrease from its 65-day average volume.
NASDAQ-100 Index Additions to Ignore for Now
The company claims it creates solutions that enable secure connections for a smarter world. The former division of Phillips only recently changed its name to NXP. For a list of additions to the NASDAQ-100, NXP has one of the more attractive valuations. The stock trades at roughly 11 times forward earnings estimates and only around two times revenue forecasts.
For one thing, the Nasdaq is not the same as it was in 2000, experts tell CNNMoney . “The Nasdaq has really grown up over the last decade. It’s a lot more mature now,” says Kim Forrest, senior equity analyst at Fort Pitt Capital. Conventional perception equates the Nasdaq with tech stocks, but its composition has changed.
Experts: Don’t see here Fear a Nasdaq Bubble
(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities classified as either Biotechnology or Pharmaceuticals. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/. About PTC Therapeutics, Inc.